Abstract 245P
Background
Currently, the ambiguous role of neutrophils (Nph) in renal cancer (RC), which is determined by their phenotype, is of considerable interest. TGF-β is able to change the expression of pro-inflammatory cytokines of Nph and their receptors, as well as stimulate the production of chemokines that attract Nph to the site of inflammation, thus forming a pro-tumor phenotype (N2). TGF-β in the tumor microenvironment induces the migration of the CD11b+ Nph population. CD11b provides adhesion, migration, degranulation of Nph. Therefore, the study was aimed at assessing the expression of the TGF-β gene, as well as CD11b receptors, by circulating Nph at different stages of RC.
Methods
The study included patients with stage I-II (n=20), stage III-IV (n=20) clear cell RC (Med 62 years) and 20 - control group (CG) (Med 60 years). The study was approved by the Ethics Committee of the IME&PС of UlSU (prot. No. 1, 01/15/2020). RNA was isolated from the fraction of peripheral blood Nph on SileksMagNA magnetic particles (Sileks, Russia). After isolation, a reverse transcription reaction was performed. Expression of the TGF-β gene was determined by quantitative reverse transcription PCR using primers (Evrogen, Russia). Immunophenotyping was performed using monoclonal antibodies to the surface antigen CD11b (Sorbent, Russia). The results were expressed as Med (Q1-Q3). Statistical processing was performed using the Statistica 13, using the Mann–Whitney U-test and the Spearman correlation coefficient (p<0.05).
Results
A significant increase in the expression of the TGF-β gene in Nph was found in patients with RC compared with the CG (0.07 (0.12-2.21) vs 0.05 (0.04-0.13), p=0, 008), and also depending on the stage: at I-II stages of RC 0.43 (0.09-1.21), at III-IV 1.91 (0.87-3.18) (p=0.05). A significant increase in the expression of CD11b on the surface of Nph was found in patients with RC 73.3±5.1% vs the CG 19.0±9.3% (p=0.001), while no relationship with the stage was found. A direct correlation was found between TGF-β and CD11b gene expression in Nph (r=0.48, p=0.01).
Conclusions
In RC, the affinity of circulating neutrophils to the tumor microenvironment increases. At the same time, the level of expression of the growth factor TGF-β increases in Nph.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract